Savara
Logotype for Savara Inc

Savara (SVRA) investor relations material

Savara Corporate presentation summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Savara Inc
Corporate presentation summary9 Nov, 2026

Disease burden and treatment gap

  • Autoimmune PAP is driven by GM-CSF autoantibodies that impair alveolar macrophage function and surfactant clearance, reducing oxygen delivery and potentially progressing to respiratory failure.

  • Symptoms include progressive breathlessness, fatigue, reduced exercise tolerance and cough; serious infections occur in 5–13% of patients and account for 18–20% of deaths.

  • Whole lung lavage is an invasive, hospital-based procedure that does not correct the underlying disease mechanism and may need repetition; long-term effects of repeated procedures are unknown.

  • Patients averaged 3.5x the comorbidity burden and 167% more outpatient visits, 505% more inpatient visits and 245% more ER visits than matched controls.

  • Diagnosis averaged 12 months after symptom onset to first physician visit, then 18 months from first visit to diagnosis; aPAP ClearPath testing aims to reduce testing barriers.

MOLBREEVI and IMPALA-2 results

  • IMPALA-2's primary endpoint, change from baseline in DLCO at Week 24, favored MOLBREEVI over placebo (LSM difference 6.00; p=0.0007); the Week 48 difference was 6.90 (p=0.0008).

  • SGRQ Total Score improved versus placebo at Week 24 (LSM difference −6.59; p=0.0072); the Week 48 difference was −4.87 (p=0.1046).

  • SGRQ Activity Score favored MOLBREEVI at Week 24 (difference −7.81; nominal p=0.0149); exercise capacity favored treatment at Week 48 (difference 0.55 peak METs; nominal p=0.0234).

  • Ground-glass opacity score improved versus placebo at Week 24 (post-hoc p=0.0004); rescue whole lung lavage was used by 7.4% of MOLBREEVI and 13.3% of placebo patients over 48 weeks.

  • Treatment discontinuation was 3%; none of the MOLBREEVI discontinuations were attributed to drug-related adverse events, and all double-blind completers entered the open-label period.

Longer-term and real-world evidence

  • Open-label follow-up showed Week 96 DLCO change of +14.7 in patients on MOLBREEVI throughout and +8.8 after placebo-to-MOLBREEVI crossover; retention was 94%.

  • In a five-patient access case series, all patients responded; reported outcomes included improved lung function and imaging, reduced symptoms, and no WLL after more than one year on treatment.

  • IMPALA and IMPALA-2 results were published in the New England Journal of Medicine, online in 2020 and 2025, respectively.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Savara earnings date

Logotype for Savara Inc
Q4 20269 Mar, 2027
Savara
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Savara earnings date

Logotype for Savara Inc
Q4 20269 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's main focus is on advancing its lead product candidate, molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). In addition to molgramostim, Savara is also developing AeroVanc, an inhaled vancomycin aimed at treating methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. Savara is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.